evaluate the pharmaceuticals company saxenda on glp-1 drugs for diabetes (liraglutide) GLP-1 medications like Ozempic, Wegovy
Description
& Stefanski, A
Oxyntomodulin has already shown to reduce food intake and bodyweight in rodents and humans ( In addition to GLP-1R/GCGR dual agonists, a chimeric peptide as dual GLP-1/GIP receptor agonists has been developed, showing enhanced therapeutic potential for obesity and related comorbidities
)
[35,36] Berberine also seems to have favorable effects on blood cholesterol and triglycerides, which is to be expected since AMPK promotes fat uptake as much as glucose uptake
Hoffman S, Alvares D, Adeli K
Eye Res
Weight loss outcomes associated with semaglutide treatment for patients with overweight or obesity
